Decoy receptor 3 is a prognostic factor in renal cell cancer

Neoplasia

Volumn 10, Issue 10, 2008, Pages 1049-1056

  Macher Goeppinger, Stephan ^a,b   Aulmann, Sebastian ^a   Wagener, Nina ^a   Funke, Benjamin ^a   Tagscherer, Katrin E ^b   Haferkamp, Axel ^a   Hohenfellner, Markus ^a   Kim, Sunghee ^c   Autschbach, Frank ^a   Schirmacher, Peter ^a   Roth, Wilfried ^a,b,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c BioPowerTech   (United States)

^d Institute of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DECOY RECEPTOR 3;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY;

EID: 54249150411     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08626     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008). Cancer statistics, 2008. CA Cancer J Clin 58, 71-96.
2. Greene FL, Page DL, Fleming ID, and Fritz A (2002). AJCC Cancer Staging Manual. 6th Edition New York: Springer.
3. Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC, and Wiltrout RH (2001). IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/ pulse IL-2 therapy. J Clin Invest 108, 51-62.
4. Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, and Sayers TJ (2002). Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol 168, 3484-3492.
5. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, et al. (1998). Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396, 699-703.
6. Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bahr M, Ohgaki H, Ashkenazi A, and Weller M (2001). Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 61, 2759-2765.
7. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, and Kwon BS (1999). A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 274, 13733-13736.
8. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, et al. (2002). TL1A is a TNF-like ligand for DR3 and TR6/ DcR3 and functions as a T cell costimulator. Immunity 16, 479-492.
9. Wu Y, Han B, Sheng H, Lin M, Moore PA, Zhang J, and Wu J (2003). Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer 105, 724-732.
10. Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, Kim NW, and McIntosh MW (2007). Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol 106, 112-118.
11. Fuhrman SA, Lasky LC, and Limas C (1982). Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6, 655-663.
12. Chen J, Zhang L, and Kim S (2004). Quantification and detection of DcR3, a decoy receptor in TNFR family. J Immunol Methods 285, 63-70.
13. Wu XX, Mizutani Y, Kakehi Y, Yoshida O, and Ogawa O (2000). Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin. Cancer Res 60, 2912-2918.
14. Gerharz CD, Ramp U, Dejosez M, Mahotka C, Czarnotta B, Bretschneider U, Lorenz I, Muller M, Krammer PH, and Gabbert HE (1999). Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control. Lab Invest 79, 1521-1534.
15. Peduto Eberl L, Guillou L, Saraga E, Schroter M, French LE, Tschopp J, and Juillerat-Jeanneret L (1999). Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas. Int J Cancer 81, 772-778.
16. Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, Soderman A, Galloway SM, Liu Q, Austin CP, et al. (2000). Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA 97, 1230-1235.
17. Arakawa Y, Tachibana O, Hasegawa M, Miyamori T, Yamashita J, and Hayashi Y (2005). Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma. Acta Neuropathol 109, 294-298.
18. Shen HW, Gao SL, Wu YL, and Peng SY (2005). Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol 11, 5926-5930.
19. Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant'Agnese PA, and Lei JY (2005). Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am J Clin Pathol 124, 282-287.
20. Tsuji S, Hosotani R, Yonehara S, Masui T, Tulachan SS, Nakajima S, Kobayashi H, Koizumi M, Toyoda E, Ito D, et al. (2003). Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int J Cancer 106, 17-25.
21. Ohshima K, Haraoka S, Sugihara M, Suzumiya J, Kawasaki C, Kanda M, and Kikuchi M (2000). Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBVor HTLV-I) associated lymphomas. Cancer Lett 160, 89-97.
22. Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida H, Hirao S, Mizuno T, and Nakajima Y (2002). The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 5, 61-68.
23. H1 response in decoy receptor 3 transgenic mice. J Immunol 175, 5135-5145.
24. Shi G, Wu Y, Zhang J, and Wu J (2003). Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo. J Immunol 171, 3407-3414.
25. Wan X, Shi G, Semenuk M, Zhang J, and Wu J (2003). DcR3/TR6 modulates immune cell interactions. J Cell Biochem 89, 603-612.
26. Zhang J, Salcedo TW, Wan X, Ullrich S, Hu B, Gregorio T, Feng P, Qi S, Chen H, Cho YH, et al. (2001). Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin Invest 107, 1459-1468.
27. Hsu TL, Chang YC, Chen SJ, Liu YJ, Chiu AW, Chio CC, Chen L, and Hsieh SL (2002). Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol 168, 4846-4853.
28. You RI, Chang YC, Chen PM, Wang WS, Hsu TL, Yang CY, Lee CT, and Hsieh SL (2008). Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3). Blood 111, 1480-1488.
29. Ficarra V, Galfano A, Mancini M, Martignoni G, and Artibani W(2007). TNM staging system for renal-cell carcinoma: current status and future perspectives. Lancet Oncol 8, 554-558.
30. Cohen H and McGovern F (2005). Renal-cell carcinoma. N Engl J Med 353, 2477-2490.
31. Kashyap MK, Kumar A, Emelianenko N, Kashyap A, Kaushik R, Huang R, Khullar M, Sharma SK, Singh SK, Bhargave AK, et al. (2005). Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers 10, 258-294.
32. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, and Gleave ME (2001). Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 3, 360-367.
33. Diegmann J, Junker K, Loncarevic IF, Michel S, Schimmel B, and von Eggeling F (2006). Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes. Neoplasia 8, 933-938.
34. Richter EN, Oevermann K, Buentig N, Storkel S, Dallmann I, and Atzpodien J (2002). Primary apoptosis as a prognostic index for the classification of metastatic renal cell carcinoma. J Urol 168, 460-464.
35. + T cell function in mice lacking the TNF superfamily member LIGHT. J Immunol 168, 4832-4835.
36. Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL, and Lin WW (2004). Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res 64, 1122-1129.
37. Gao S, Lee P, Wang H, Gerald W, Adler M, Zhang L, Wang YF, and Wang Z (2005). The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol 19, 1792-1802.
38. Gavrielides MV, Gonzalez-Guerrico AM, Riobo NA, and Kazanietz MG (2006). Androgens regulate protein kinase Cdelta transcription and modulate its apoptotic function in prostate cancer cells. Cancer Res 66, 11792-11801.
39. Langner C, Ratschek M, Rehak P, Schips L, and Zigeuner R (2004). Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. J Urol 171, 611-614.
40. Yamana K, Bilim V, Hara N, Kasahara T, Itoi T, Maruyama R, Nishiyama T, Takahashi K, and Tomita Y (2005). Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer 93, 544-551.
41. Mild G, Bachmann F, Boulay JL, Glatz K, Laffer U, Lowy A, Metzger U, Reuter J, Terracciano L, Herrmann R, et al. (2002). DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. Int J Cancer 102, 254-257.
42. Shi G, Mao J, Yu G, Zhang J, and Wu J (2005). Tumor vaccine based on cell surface expression of DcR3/TR6. J Immunol 174, 4727-4735.